

Dr Hiroko Ohgaki
 Head, Section of Molecular Pathology
 International Agency for Research on Cancer (IARC)
 150 Cours Albert Thomas
 69372 Lyon Cedex 08
 France
 Tel. +33 (0)4 72 73 85 34
 E-mail. ohgaki@iarc.fr



Academic degrees

Doctor of Veterinary Medicine (DVM), Tokyo University of Agriculture and Technology, Japan (1979)
 Ph.D (Medical Science), Faculty of Medicine, University of Tokyo, Japan (1986)

Professional training and appointments

1980-1989	Research Associate, Biochemistry Division, National Cancer Center Research Institute, Japan (Laboratory of Dr. S. Sato and Dr. T. Sugimura)
1989-1990	Postdoctoral Fellow, Institute of Toxicology, Federal Institute of Technology and University of Zurich, Switzerland (Laboratory of Dr. W.K. Lutz)
1990-1992	Postdoctoral Fellow, Institute of Neuropathology, University of Zurich, Switzerland (Laboratory of Dr. P. Kleihues)
1992-1995	Special Expert of Pathology, Laboratory of Experimental Carcinogenesis, Division of Cancer Etiology, National Cancer Institute, NIH, USA (Laboratory of Dr. S. S. Thorgeirsson)
1995-2004	Chief, Unit of Molecular Pathology, International Agency for Research on Cancer (IARC), Lyon, France
2004-2009	Head, Pathology Group, IARC, Lyon, France
2006-present	Series Editor, WHO Classification of Tumours Series, 4 th edition
2009-present	Head, Section of Molecular Pathology, IARC, Lyon, France

Prizes and honors

Incitement Award of the Japanese Cancer Association (1985)
 Lucien J. Rubinstein Award of the American Association of Neuropathologists (1996)
 Lucien J. Rubinstein Award of the American Association of Neuropathologists (2001)

Editorial board

Brain Pathology (2000-present)

Journal of Neuropathology and Experimental Neurology (2003-2006)
 Acta Neuropathologica (2005-2016)
 Cancer Science (Associate Editor) (2006-present)
 Neuro-Oncology (2007-present)
 Brain Tumor Pathology (International Advisory Board) (2010-present)

Selected publications

- Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. *Am J Pathol.* 174: 1149-1153 (2009)
- Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. *Acta Neuropathol.* 117: 653-656 (2009)
- Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. *Clin Cancer Res.* 15: 6002-6007 (2009)
- Nobusawa S, Lachuer J, Wierinck A, Kim YH, Huang J, Legras C, Kleihues P, Ohgaki H. Intratumoral patterns of genomic imbalance in glioblastoma. *Brain Pathol.* 20: 936-944 (2010)
- Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H. Molecular classification of low-grade diffuse gliomas. *Am J Pathol.* 177: 2708-2714 (2010)
- Nagaishi M, Kim YH, Mittelbronn M, Giangaspero F, Paulus W, Brokinkel B, Vital A, Tanaka Y, Nakazato Y, Legras-Lachuer C, Lachuer J, Ohgaki H. Amplification of the STOML3, FREM2, and LHFP genes is associated with mesenchymal differentiation in gliosarcoma. *Am J Pathol,* 180: 1816-1823 (2012)
- Kim YH, Nonoguchi N, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Mariani L, Giangaspero F, Tanaka Y, Nakazato Y, Vital A, Mittelbronn M, Perry A, Ohgaki H. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss *Brain Pathol* 22:834-840 (2012).
- Ohgaki H and Kleihues P: Definition of primary and secondary glioblastoma. *Clin Cancer Res* 19:764-772 (2013)
- Nonoguchi N, Ohta T, Oh J-E, Kim Y-H, Kleihues P, Ohgaki H. *TERT* promoter mutations in primary and secondary glioblastomas. *Acta Neuropathologica* 126: 931-937 (2013)
- Kim YH, Ohta T, Le Calvez-Kelm F, McKay J, Voegelé C, Durand G, Mittelbronn M, Kleihues P, Paulus W, Ohgaki H. *TP53*, *MSH4*, and *LATS1* Germline Mutations in a Family with Clustering of Nervous System Tumors. *Am J Pathol* 184: 2374-2381 (2014)

- Oh J-E, Ohta T, Satomi K, Foll M, Durand G, McKay J, Le Calvez-Kelm F, Mittelbronn M, Brokinkel B, Paulus W, Ohgaki H. Alterations in the NF2 / LATS1 / LATS2 / YAP pathway in schwannomas. *J Neuropathol Exp Neurol*. 74: 952-959 (2015)
- Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumours of the Central Nervous System: a Summary. *Acta Neuropathologica* 131: 803-820 (2016)
- Oh J-E, Ohta T, Nonoguchi N, Satomi K, Capper D, Pierscianek D, Sure U, Vital A, Paulus W, Mittelbronn M, Antonelli M, Kleihues P, Giangaspero F, Ohgaki H. Genetic alterations in gliosarcoma and giant cell glioblastoma. *Brain Pathology*, 26: 517-522 (2016)
- Wang Q, Satomi K, Oh J-E, Hutter B, Brors B, Diessl N, Liu H-K, Wolf S, Wiestler O, Kleihues P, Koelsch B, Kindler-Röhrborn A, Ohgaki H. *Braf* mutations initiate the development of rat gliomas induced by postnatal exposure to *N*-ethyl-*N*-nitrosourea (ENU). *Am J Pathol*, 186: 2569-2576 (2016)

Books

- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO Classification of Tumours of the Central Nervous System, 4th edition, IARC, Lyon (2007).
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO Classification of Tumours of the Central Nervous System, revised 4th edition, IARC, Lyon (2016)